Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts

Journal of Cellular Physiology

Volumn 202, Issue 1, 2005, Pages 87-99

  Chen, James S ^a   Faller, Douglas V ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CYCLIN E; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN P27; TRICHOSTATIN A;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; ENZYME REPRESSION; FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN STABILITY; RAT;

ANIMALS; BALB 3T3 CELLS; BUTYRATES; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENZYME INHIBITORS; FEEDBACK, BIOCHEMICAL; FIBROBLASTS; G1 PHASE; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; MICE; NIH 3T3 CELLS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

MURINAE;

EID: 10044280340     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20094     Document Type: Article

References (72)

1. Archer SY, Meng SF, Shei A, Hodin RA. 1998. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95:6791-6796.
2. Atweh GF, Sutton M, Nassif I, Boosalis V, Dover GJ, Wallenstein S, Wright E, Mcmahon L, Stamatoyannopoulos G, Faller DV, Perrine SP. 1999. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 93:1790-1797.
3. Boffa LC, Lupto JR, Mariani MR, Ceppi M, Newmark HL, Scamati A, Lipkin M. 1992. Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. Cancer Res 52:5906-5912.
4. Boosalis MS, Ikuta T, Pace BS, daFonseca S, White GL, Faller DV, Perrine SP. 1997. Abrogation of IL-3 requirements and stimulation of hematopoietic cell proliferation in vitro and in vivo by carboxylic acids. Blood Cells Mol Dis 23:434-442.
5. Boosalis MS, Bandyopadhyay R, Bresnick EH, Pace BS, VanDeMark K, Zhang BH, Faller DV, Perrine SP. 2001. Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood 97:3259-3267.
6. Campisi J, Medrano EE, Morreo G, Pardee AB. 1982. Restriction point control of cell growth by a labile protein: Evidence for increased stability in transformed cells. Proc Natl Acad Sci USA 79:436-440.
7. Carrano AC, Eytan E, Hershko A, Pagano M. 1999. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1:193-199.
8. Chen JS, Faller DV, Spanjaard RA. 2003. Short-chain fatty acid inhibitors of histone deacetylases: Promising anticancer therapeutics? Curr Cancer Drug Targets 3:219-236.
9. Chong KL, Feng L, Schappert K, Meurs E, Donahue TF, Friesen JD, Hovanessian AG, Williams BRG. 1992. Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2. EMBO J 11:1553-1562.
10. Coats S, Flanagan WM, Nourse J, Roberts JM. 1996. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 272:877-880.
11. ConnellCrowley L, Elledge SJ, Harper JW. 1998. G1 cyclin-dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts. Curr Biol 8:65-68.
12. Craig C, Wersto R, Kim M, Ohri E, Li Z, Katayose D, Lee SJ, Trepel J, Cowan K, Seth P. 1997. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 14:2283-2289.
13. Cummings JH, Pomare EW, Branch WJ, Naylor CP, MacFarlane GT. 1987. Short-chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28:1221-1227.
14. Faller DV, Perrine SP. 1995. Butyrate in the treatment of sickle cell disease and β-thalassemia. Curr Opin Hemat 2:109-117.
15. Faller DV, Mentzer SJ, Perrine SP. 2001. Induction of the Epstein-Barr Virus Thymidine Kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for EBV-associated malignancies. Curr Opin Oncol 13:367.
16. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM. 1996. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85:733-744.
17. Freytag SO, Geddes TJ. 1992. Reciprocal regulation of adipogenesis by Myc and C/EBPalpha. Science 256:379-382.
18. Guo N, Faller DV, Vaziri C. 2000. A novel DNA damage checkpoint involving post-transcriptional regulation of cyclin A expression. J Biol Chem 275:1715-1722.
19. Hengst L, Reed SI. 1996. Translational control of p27Kip1 accumulation during the cell cycle. Science 271:1861-1864.
20. Hirschfeld A, Bressler J. 1987. Effect of sodium butyrate on S-100 protein levels and the cAMP response. J Cell Physiol 133:158-162.
21. Hung WC, Chang HC, Pan MR, Lee TH, Chuang LY. 2000. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol Pharmacol 58:1398-1403.
22. Ikuta T, Atweh GF, Boosalis V, White GL, da Fonseca S, Boosalis MS, Faller DV, Perrine SP. 1998a. Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis. Ann NY Acad Sci 850:87-99.
23. Ikuta T, Kan YW, Swerdlow PS, Faller DV, Perrine SP. 1998b. Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy. Blood 92:2924-2933.
24. Inoue T, Kamiyama J, Sakai T. 1999. Sp1 and NF-Y synergistically mediate the effect of vitamin D-3 in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 274:32309-32317.
25. Kim YB, Ki SW, Yoshida M, Horinouchi S. 2000. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J Antibiot (Tokyo) 53:1191-1200.
26. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A. 1996. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85:721-732.
27. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR, Roberts JM. 1992. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257:1689-1694.
28. Kouzarides T. 1999. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Develop 9:40-48.
29. Liou JS, Chen CY, Chen JS, Faller DV. 2000. Oncogenic Ras mediates apoptosis in response to protein kinase C inhibition through the generation of reactive oxygen species. J Biol Chem 275:39001-39011.
30. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. 1999. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313-323.
31. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. 2000. Regulation of E2F1 activity by acetylation. EMBO J 19:662-671.
32. Marzio G, Wagener C, Gutierrez MI, Cartwright P, Helin K, Giacca M. 2000. E2F family members are differentially regulated by reversible acetylation. J Biol Chem 275:10887-10892.
33. Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP, Faller DV. 1998. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr Virus (EBV)-associated lymphoma. Blood Cells Mol Dis 24:114-123.
34. Mentzer SJ, Perrine SP, Faller DV. 2001. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: Pharmacological re-activation of viral target genes with arginine butyrate. Transplant Infec Dis 3:185.
35. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. 1999. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 13:1181-1189.
36. Morgan DO. 1997. Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261-291.
37. Muller D, Thieke K, Burgin A, Dickmanns A, Eilers M. 2000. Cyclin E-mediated elimination of p27 requires its interaction with the nuclear pore-associated protein mNPAP60. EMBO J 19:2168-2180.
38. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Hori I, Loh DY. 1996. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720.
39. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685.
40. 1 events and regulation of cell proliferation. Science 246:60-68.
41. Perrine SP, Faller DV. 1993. Butyrate-induced reactivation of the fetal globin genes - A molecular treatment for the β-hemoglobinopathies. Experientia 49:133-137.
42. Perrine SP, Greene MF, Faller DV. 1985. Delay of the fetal globin switch in infants of diabetic mothers. N Engl J Med 312:334-338.
43. Perrine SP, Rudolph A, Faller DV, Roman C, Cohen RA, Chen S-J, Kan YW. 1988. Butyrate infusions in the ovine fetal delay the biologic clock for globin gene switching. Proc Natl Acad Sci USA 85:8540-8542.
44. Perrine S, Miller B, Papayannopoulou T, Faller DV, Vichinsky E, Rudolph A, Kan YW. 1989a. Butyrate analogues inhibit gamma-beta globin switching in the ovine fetus and in HbSS and beta thalassemia erythroid progenitors. Prog Clin Biol Res 316:341-350.
45. Perrine SP, Miller BA, Faller DV, Cohen RA, Vichinsky EP, Hurst D, Lubin BH, Papayannopoulou T. 1989b. Sodium butyrate stimulates fetal globin gene expression in erythroid progenitors of children with HbSS and beta thalassemia. Blood 74:454-460.
46. Perrine SP, Swerdlow P, Faller DV, Qin G, Rudolph AM, Reczek J, Kan YW. 1989c. Butyric acid modulates developmental globin gene switching in man and sheep. Adv Exp Med Biol 271:177-183.
47. Perrine SP, Faller DV, Swerdlow P, Miller BA, Bank A, Sytkowski AJ, Reczek J, Rudolph AM, Kan YW. 1990. Stopping the biologic clock for globin gene switching. Ann NY Acad Sci 612:134-140.
48. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP, Olivieri NF. 1993. A short-term trial of butyrate to stimulate fetal-globin gene expression in the β-globin disorders. N Engl J Med 328:81-86.
49. Perrine SP, Olivieri NF, Faller DV, Vichinsky EP, Dover GJ, Ginder GD. 1994. Butyrate derivatives: New agents for stimulating fetal globin production in the β globin disorders. Am J Pediatr Hematol Oncol 16:67-71.
50. Polyak K, Lee M-H, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. 1994. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
51. Pouillart PR. 1998. Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies - Minireview. Life Sci 63:1739-1760.
52. Prasad KN, Sinha PK. 1976. Effect of sodium butyrate on mammalian cells in culture: A review. In Vitro 12:125-132.
53. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. 1999. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 96:7797-7802.
54. Redner RL, Wang JX, Liu JM. 1999. Chromatin remodeling and leukemia: New therapeutic paradigms. Blood 94:417-428.
55. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. 2000. Histone deacetylase inhibitor selectively induces p21(WAF1) expression and gene-associated histone acetylation. Proc Nat Acad Sci USA 97: 10014-10019.
56. Rivard N, L'Allemain G, Bartek J, Pouyssegur J. 1996. Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. J Biol Chem 271:18337-18341.
57. Russell P. 1998. Checkpoints on the road to mitosis. Trends Biochem Sci 23:399-402.
58. Sealy L, Chalkley R. 1978. The effect of sodium butyrate on histone modification. Cell 14:115-121.
59. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. 2000. Multiple functions of p27(Kip1) and its alterations in tumor cells: A review. J Cell Physiol 183:18-27.
60. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, Nakayama K, Kitagawa M. 1999. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 274:13886-13893.
61. Toyoshima H, Hunter T. 1994. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67-74.
62. Trapasso F, Iuliano R, Boccia A, Stella A, Visconti R, Bruni P, Baldassarre G, Santoro M, Viglietto G, Fusco A. 2000. Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). Mol Cell Biol 20:9236-9246.
63. Tsihlias J, Kapusta L, Slingerland J. 1999. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 50:401.
64. VanDeMark K, Chen JS, Steliou K, Perrine SP, Faller DV. 2003. alpha-lipoic acid induces p27(Kip)-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J Cell Physiol 194:325-340.
65. Vaziri C, Stice L, Faller DV. 1998. Butyrate-induced G(1) arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ 9:465-474.
66. Vigushin DM, Coombes RC. 2002. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13:1-13.
67. Vlach J, Hennecke S, Amati B. 1997. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 16:5334-5344.
68. Wharton W, Savell J, Cress WD, Seto E, Pledger WJ. 2000. Inhibition of mitogenesis in Balb/c-3T3 cells by Trichostatin A. Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J Biol Chem 275:33981-33987.
69. Winston J, Dong F, Pledger WJ. 1996. Differential modulation of G(1) cyclins and the Cdk inhibitor p27(kip1) by platelet-derived growth factor and plasma factors in density-arrested fibroblasts. J Biol Chem 271:11253-11260.
70. Wintersberger E, Mudrak I, Wintersberger U. 1983. Butyrate inhibits mouse fibroblasts at a control point in the G1 phase. J Cell Biochem 21:239-247.
71. Zhang Y, Lin SC. 1997. Molecular characterization of the cyclin-dependent kinase inhibitor p27 promoter. Biochim Biophys Acta 1353:307-317.
72. Zhang HS, Gavin M, Dahiya A, Postigo AA, Ma D, Luo RX, Harbour JW, Dean DC. 2000. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 101:79-89.